ArticleHeliyon2023
Antibacterial mechanism of action and in silico molecular docking studies of
Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- GC-MS Analyses and Bioactivity Evaluation of Origanum minutiflorum Essential Oil: Antioxidant, Antibacterial, Genotoxicity, and Molecular Docking Studies.Chemistry & biodiversity · 2026Article
- Antibiofilm Activity of Three Essential Oils Against ESBL-ProducingAntibiotics (Basel, Switzerland) · 2026Article
- In-silico study of the bioactive compounds of Blighia sapida koenig revealed a novel Plasmodium falciparum dihydroorotate dehydrogenase inhibitor for malaria.Scientific reports · 2026Article
- An integrative in silico and in vitro synergy of Cinnamomum verum essential oil and cinnamaldehyde with imipenem against extensively drug-resistant Gram-negative bacteria.Scientific reports · 2026Article
- Review
- Integrating computational approaches to uncover β-lactamase-associated resistance in diarrheagenic Escherichia coli from pediatric patients.Scientific reports · 2025Article
- Natural compounds for colistin-resistant Acinetobacter baumannii biofilm control: eugenol, cinnamaldehyde, and carvacrol.Molecular biology reports · 2025Article
- Antibacterial and antibiofilm efficacy of eugenol, carvacrol, and cinnamaldehyde against colistin-resistant Klebsiella pneumoniae.Molecular biology reports · 2025Article
- The synergistic effect ofFrontiers in pharmacology · 2025Article
- Chemical Profiling and Antibacterial Potential of Methanol Extract ofCurrent topics in medicinal chemistry · 2025Article
- Synthesis molecular docking and DFT studies on novel indazole derivatives.RSC advances · 2024Article
- Article
- Phenotypic diversity and provenance variation ofPeerJ · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The primary objective of this research work was to study the antibacterial effects of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.